Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 8/20 | 0.40 |
| ▸ | HTR2A | P28223 | 6/20 | 0.34 |
| ▸ | PNMT | P11086 | 1/20 | 0.34 |
| ▸ | HRH1 | P35367 | 4/20 | 0.33 |
| ▸ | HTR2C | P28335 | 2/20 | 0.31 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.30 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2310833 | 0.85 | FFAR1 (0.30) | — | |
| SCHEMBL1041269 | 0.81 | — | — | |
| SCHEMBL6868808 | 0.81 | GABRA1 (0.33) | — | |
| SCHEMBL8813732 | 0.76 | — | — | |
| SCHEMBL1042696 | 0.72 | ALDH1A1 (0.32) | HTR2AHRH1 | |
| SCHEMBL150109 | 0.72 | AHR (0.33) | — | |
| SCHEMBL2308035 | 0.72 | FFAR1 (0.31) | — | |
| SCHEMBL8411757 | 0.72 | ALDH1A1 (0.39) | — | |
| SCHEMBL9160477 | 0.72 | MAOA (0.39) | HTR2AHRH1HTR2C | |
| SCHEMBL36333 | 0.72 | MAOA (0.39) | HTR2AHRH1HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050176619-A1 | N-[[1-[[2-(diethylamino)ethyl]amino]-7-methoxy-9-oxothioxanthen-4-yl]-methyl]formamide, or a pharmaceutically acceptable acid-addition salt thereof, and to the method of use thereof in the treatment of tumors and cancers. | SANOFI-AVENTIS (FR) | 2005-08-11 | — | — | US | disclosed |
| EP-1406699-A1 | ANTITUMORAL FORMULATIONS OF THIOXANTHENONE | Sanofi-Aventis (FR) | 2004-04-14 | — | — | EP | disclosed |
| WO-2003002202-A1 | ANTITUMORAL FORMULATIONS OF THIOXANTHENONE | SANOFI-SYNTHELABO (FR) | 2003-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176619-A1 | N-[[1-[[2-(diethylamino)ethyl]amino]-7-methoxy-9-oxothioxanthen-4-yl]-methyl]formamide, or a pharmaceutically acceptable acid-addition salt thereof, and to the method of use thereof in the treatment of tumors and cancers. | DOHH, MTX2, MTX1 | TAAR1 3496/4885HTR2A 2309/4885PNMT 865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.